Risk Stratification of Clostridioides difficile Infection
Clostridioides difficile infection should be risk-stratified into three severity categories—nonsevere, severe, and fulminant—based on specific clinical and laboratory parameters, with white blood cell count ≥15,000 cells/µL or serum creatinine ≥1.5 mg/dL defining severe disease, and hypotension, shock, ileus, or megacolon defining fulminant disease. 1
Primary Disease Severity Classification
The 2018 IDSA/SHEA guidelines provide the definitive framework for stratifying CDI severity 1:
Nonsevere CDI
- White blood cell count <15,000 cells/µL AND
- Serum creatinine <1.5 mg/dL
Severe CDI
- White blood cell count ≥15,000 cells/µL OR
- Serum creatinine ≥1.5 mg/dL (or ≥1.5 times baseline)
Fulminant (Severe-Complicated) CDI
Any of the following:
- Hypotension or shock requiring vasopressors
- Ileus or significant abdominal distension
- Megacolon on imaging
- Mental status changes
- End-organ failure (requiring ICU admission)
Important caveat: These laboratory cutoffs have limitations in patients with baseline leukopenia (hematologic malignancies) or end-stage renal disease where creatinine is chronically elevated. Clinical judgment must supplement these criteria 2.
Risk Stratification for Recurrence
Beyond initial severity, you must assess recurrence risk, as approximately 25% of patients will experience at least one additional episode 1.
High-Risk Factors for Recurrence 1, 3:
Patient factors:
- Age ≥65 years (strongest demographic predictor) 4, 5
- Multiple prior CDI episodes
- Defective humoral immune response to C. difficile toxins
- Severe underlying comorbidities
Treatment-related factors:
- Continued antibiotic use during or after CDI treatment (most modifiable risk factor) 1, 3
- Longer duration of antibiotic therapy 3
- Poor or partial response to initial treatment 3
- Concomitant proton pump inhibitor use 1
Healthcare exposure:
Quantitative Risk Assessment
A validated risk score for elderly patients assigns points for 4:
- Hospitalization, nursing home stay, or antibiotics in prior year
- Inflammatory bowel disease, chronic liver disease, chronic kidney disease, or cardiac disease
- Age ≥75 years
- Northeast U.S. residence
A score ≥7 points (present in 18.8% of Medicare beneficiaries) indicates high risk with negative predictive value of 98.7%.
Practical Risk Stratification Algorithm
Step 1: Assess disease severity at presentation
- Check WBC count and serum creatinine
- Evaluate for signs of shock, ileus, or organ failure
- This determines initial treatment intensity
Step 2: Identify recurrence risk factors
- Document number of prior CDI episodes
- Count current antibiotic exposures (risk increases 1.2-fold per additional antibiotic) 5
- Note recent healthcare exposures
- Assess comorbidity burden
Step 3: Stratify into treatment categories
- Nonsevere + low recurrence risk: Standard 10-day therapy
- Nonsevere + high recurrence risk: Consider fidaxomicin over vancomycin 1
- Severe disease: Vancomycin or fidaxomicin (never metronidazole) 1
- Fulminant disease: High-dose vancomycin (500 mg PO QID) + IV metronidazone ± rectal vancomycin; immediate surgical consultation 1, 2
Common Pitfalls to Avoid
Do not use metronidazole for severe disease—it has inferior outcomes and should only be considered for nonsevere CDI when vancomycin/fidaxomicin are unavailable 1
Do not rely solely on laboratory values in immunocompromised patients—leukopenia may mask severity in hematologic malignancy patients 2, 6
Do not overlook antibiotic stewardship—discontinuing inciting antibiotics is a strong recommendation that directly impacts both cure and recurrence rates 1
Do not ignore treatment response—poor initial response is an independent predictor of recurrence and should trigger escalation of therapy 3
The evidence consistently demonstrates that antibiotic exposure remains the single most important modifiable risk factor across all studies 7, 5, 6, making aggressive antibiotic stewardship the cornerstone of both prevention and recurrence reduction.